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The Role of Proximal Nephron in Cyclophospha­
mide­Induced  Water Retention: Preliminary Data
Cyclophosphamide is clinically useful in treating malignancy and rheumatologic 
disease, but has limitations in that it induces hyponatremia. The mechanisms 
by which cyclophosphamide induces water retention in the kidney have 
yet to be identified. This study was undertaken to test the hypothesis that 
cyclophosphamide may produce water retention via the proximal nephron, where 
aquaporin-1 (AQP1) and aquaporin-7 (AQP7) water channels participate in water 
absorption. To test this hypothesis, we gave a single dose of intraperitoneal 
cyclophosphamide to male Sprague-Dawley rats and treated rabbit proximal 
tubule cells (PTCs) with 4-hydroperoxycyclophosphamide (4-HC), an active 
metabolite of cyclophosphamide. In the short-term 3-day rat study, AQP1 protein 
expression was significantly increased in the whole kidney homogenates by 
cyclophosphamide administration at 48 (614 ± 194%, P < 0.005), and 96 (460 
± 46%, P < 0.05) mg/kg BW compared with vehicle-treated controls. Plasma 
sodium concentration was significantly decreased (143 ± 1 vs. 146 ± 1 mEq/
L, P < 0.05) by cyclophosphamide 100 mg/kg BW in the long-term 6-day rat 
study. When primary cultured rabbit PTCs were treated with 4-HC for 24 hours, 
the protein expressions of AQP1 and AQP7 were increased in a dose-dependent 
manner. Quantitative polymerase chain reaction revealed no significant changes 
in the mRNA levels of AQP1 and AQP7 from cyclophosphamide-treated rat renal 
cortices. From these preliminary data, we conclude that the proximal nephron 
may be involved in cyclophosphamide-induced water retention via AQP1 and 
AQP7 water channels. Further studies are required to demonstrate intracellular 
mechanisms that affect the expression of AQP proteins. 
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of serious water retention and dilutional hyponatremia 
as a consequence of the water-retaining drugs
1). Thus, 
hyponatremia is one of the common electrolyte abnor-
malities induced by drugs.  
Cyclophosphamide is an alkylating agent that is useful 
for the treatment of malignancy and rheumatologic 
Introduction
Some pharmacologic agents have been shown to have 
water-retaining properties. Whereas the antidiuretic 
actions are used to advantage in the treatment of patients 
with diabetes insipidus, there have been numerous reports 8      S Kim et al.• The Role of Proximal Nephron in Cyclophosphamide-Induced  Water Retention
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disease. It can produce an antidiuretic effect when injected 
intravenouisly into water-loaded patients
2, 3). We recently 
reported that cyclophosphamide-induced hyponatremia 
is not rare even when low-dose pulse cyclophosphamide 
is used
4). However, the mechanisms by which cyclo-
phosphamide induces water retention in the kidney have 
not been defined.
The main water channels participating in water con-
servation along the renal tubule are aquaporin-1 (AQP1) 
and aquaporin-2 (AQP2). AQP1 is abundant in the apical 
and basolateral membranes of renal proximal tubules and 
descending thin limbs. AQP2 is localized in the apical 
membrane and in intracellular vesicles which are targeted 
to the apical plasma membranes when stimulated by 
vasopressin
5). The traditional view was that some drugs 
including cyclophosphamide may potentiate the action of 
vasopressin on the kidney, but this explanation has never 
been verified in cases with cyclophosphamide-induced 
water retention. 
In this study, we hypothesized that in producing 
water retention in the proximal tubule and Henle's thin 
descending limb, the AQP1 water channel may have a 
role in cyclophosphamide-induced hyponatremia. To test 
this hypothesis, the expression of AQP1 was investigated 
both in vivo and in vitro after the administration 
of cyclophosphamide and its active metabolite 4- 
hydroperoxycyclophosphamide (4-HC), respectively.
Materials and Methods
1. Animal experiments of cyclophosphamide admi-
nistration
Specific pathogen-free male Sprague-Dawley rats (Orient 
Bio Inc., Seongnam, Korea) weighing 240‒260 g, were used 
for two animal experiments of single cyclophosphamide 
administration. For the short-term 3-day study (Animal 
Experiment I), different doses (12, 24, 48, and 96 mg/
kg BW) of intraperitoneal cyclophosphamide were 
administered to rats in Animal Experiment I. Control rats 
received an injection of the vehicle (normal saline) solution 
only. All rats were provided with a gelled agar (1%) diet, so 
that adequate water loading (52 mL/200 g BW per day) and 
a fixed amount of daily regular rat chow (18 g/200 g BW 
per day) were given to each rat. In addition, they were freely 
accessible to drinking water.
For the long-term 6-day study (Animal Experiment 
II), a large dose (100 mg/kg BW) of intraperitoneal 
cyclophosphamide was given to rats in Animal Experiment 
II. For water loading, drinking water containing 600 mM 
sucrose was supplied. Rats spontaneously drink large 
amounts of this fluid, causing a water diuresis
6). Serum 
and urine samples were collected at the time each rat was 
killed for determination of electrolytes and osmolality. The 
experimental protocols were approved by the institutional 
Animal Care and Use Committee of Hanyang University. 
2. Proximal tubular cell culture and treatment with 4-HC
Primary cultured renal proximal tubular cells (PTCs) 
of New Zealand White male rabbits (1.5‒2.0 kg) from 
Dae Han Experimental Animal (Chungju, Korea) were 
prepared as previously described
7). The PTCs were grown 
in DMEM/F-12 medium supplemented with 15 mM 
HEPES and 20 mM sodium bicarbonate (pH 7.4). Three 
other growth supplements (5 μg/mL insulin, 5 μg/mL 
transferrin, and 5×10
‒8 M hydrocortisone) were added 
immediately before the medium was used. The kidneys 
from a rabbit were perfused through the renal artery, 
first with phosphate-buffered saline (PBS) and then with 
medium containing 0.5% iron oxide. Renal cortical slices 
were prepared and homogenized. The homogenate was 
poured sequentially through 253- and 83-μm mesh filters. 
Tubules and glomeruli caught by the 83-μm filter were 
transferred into sterile medium. The glomeruli (which 
contained the iron oxide) were removed using a magnetic 
stir bar. The remaining proximal tubules were incubated 
briefly in a medium containing 0.125 mg/mL collagenase 
and 0.025% soybean trypsin inhibitor. The tubules were 
then washed by centrifugation, resuspended in a medium 
containing the three supplements, and transferred into Electrolyte Blood Press 9:7-15, 2011 • doi: 10.5049/EBP.2011.9.1.7    9
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tissue culture dishes. The medium was changed 1 day after 
plating and every 2 days thereafter. The primary cultured 
rabbit kidney PTCs were maintained at 37°C in a 5% CO2 
humidified environment and a serum-free basal medium 
amended with the 3 growth supplements.
4-HC was obtained from Niomec (Bielefeld, Germany). 
According to the previous study applying on the human 
hair follicle
8), 4 different 4-HC concentrations (1, 3, 10, and 
30 μmol/L) were prepared on ice in Williams’ E medium 
immediately before use because of the short half-life of 
the compound
9). These concentrations were previously 
selected to imitate relevant serum levels of 4-HC in patients 
receiving moderate- to high-dose cyclophosphamide 
therapy
10-12). Cells were harvested in 1 to 3 days after the 
4-HC treatment for immunoblot analysis.
3. Preparation of cytosolic and membrane fraction from 
PTCs
Once confluent cultures were treated according to the 
indicated conditions, the media was removed and PTCs 
were washed twice with ice-cold PBS, scraped, harvested 
by microcentrifugation, and resuspended in Buffer A (137 
mM NaCl, 8.1 mM Na2HPO4, 2.7 mM KCl, 1.5 mM 
KH2PO4, 2.5 mM EDTA, 1 mM dithiothreitol, 0.1 mM 
phenylmethanesulfonyl fluoride, 10 μg/mL leupeptin [pH 
7.5]). Resuspended cells were then lysed mechanically on 
ice by trituration with a 21.1-gauge needle. To prepare 
the cytosolic and particulate fractions, the lysates were 
centrifuged at 1,000 μg for 10 minutes at 4°C, after which 
the supernatants were centrifuged at 100,000 μg for 1 
h at 4°C. The particulate fraction, which contained the 
membranes, was washed twice and resuspended in Buffer 
A containing 1% (v/v) Triton X-100. Protein levels in each 
fraction were quantified using the Bradford procedure
13).
4. Immunoblot analysis
When each animal experiment was finished, whole 
kidneys or manually dissected slices of renal cortex were 
homogenized in a buffer containing 250 mM sucrose, 10 
mM triethanolamine, 1 μg/mL leupeptin, and 0.1 mg/
mL phenylmethylsulfonyl fluoride titrated to pH 7.6.   
Coomassie-stained "loading gels" were done to assess the 
quality of the protein by sharpness of the bands and to 
adjust protein concentrations before immunoblotting
14). 
For immunoblotting, the proteins were transferred 
electrophoretically from unstained gels to nitrocellulose 
membranes (Bio-Rad, Hercules, CA, USA). After being 
blocked with 5% skim milk in PBS-T (80 mM Na2HPO4, 
20 mM NaH2PO4, 100 mM NaCl, 0.1 percent Tween-20, 
pH 7.5) for 30 minutes, membranes were probed overnight 
at 4°C with the respective primary antibodies. The 
secondary antibody was goat anti-rabbit IgG conjugated 
to horseradish peroxidase (Pierce, Rockford, IL, USA). 
Sites of antibody-antigen reaction were viewed using 
enhanced chemiluminescence substrate (ECL™ RPN 2106; 
Amersham Pharmacia Biotech, Buckinghamshire, UK) 
before exposure to X-ray film (Hyperfilm; Amersham 
Pharmacia Biotech, Buckinghamshire, UK). Relative 
quantification of the band densities from immunoblots 
was carried out by densitometry using a laser scanner and 
ImageQuaNT software (Molecular Analyst version 1.5, 
Bio-Rad, Hercules, CA, USA). 
5. Quantitative polymerase chain reaction (QPCR)
Total RNA was isolated from the rat whole kidneys 
with the TRIzol
® Reagent (Life Technologies, Carlsbad, 
CA, USA). RNA was quantified by spectrophotometry, 
and cDNA synthesis was performed on 3 μg of RNA with 
SuperScript
® III Reverse Transcriptase (Life Technologies, 
Carlsbad, CA, USA). For quantitative polymerase chain 
reaction (PCR), 100 ng of cDNA served as a template for 
PCR amplification using Brilliant SYBR green QPCR 
master mix according to the manufacturer’s instructions 
(FastStart DNA Master SYBR Green I, Roche Molecular 
Biochemicals). Serial dilution (1 ng‒1 fg/μL) of cDNA 
was used as a template for generation of a standard curve. 
Nested primers were used to amplify standards and kidney 
cDNA samples as follows: GGC TTC AAT TAC CCA 
CTG GA (sense) and TTG ATC CCA CAG CCA GTG 
TA (antisense) for AQP1 (498 bp)
15), TCC AGC AGT TGT 10      S Kim et al.• The Role of Proximal Nephron in Cyclophosphamide-Induced  Water Retention
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CAC TGG C (sense) and TAA GCA CAG TCC CCC 
AGA AGG (antisense) for AQP2 (562 bp)
16), CCA CAA 
TGG AAG GTT CTG TG (sense) and CCA ATC TCT 
AAG AAC CCT GT (antisense) for AQP7 (884 bp)
17), 
and TGC TGT GAC AGG TGT GTT AGG TCA (sense) 
and CCA TGG TTC TGC AAA TCG GG (antisense) for 
vasopressin-2 receptor (625 bp)
18). 
Standards and unknown samples were amplified in 
duplicate in 96-well plates. The thermal profile of the 
LightCycler
® Instrument (Roche Molecular Biochemicals, 
Mannheim, Germany) was optimized with an initial 
denaturation of 10 minutes at 95°C and 40 amplification 
cycles with each 15 seconds at 95°C, 5 seconds at 58°C and 
10 seconds at 72°C. The comparative Ct method was used 
to determine the relative amounts of target-mRNA levels 
calculated for each sample by expressing the target-mRNA 
level as a percentage of GAPDH mRNA levels. Ct ratios were 
analyzed using the LightCycler
® Software (Version 4.05). 
Specificity was ensured by postrun melting curve analysis. 
6. Primary antibodies
For immunoblot analysis from rat kidneys, we used 
polyclonal antibodies against AQP1 and AQP2
19). They 
were kindly donated by Dr. Mark Knepper at the National 
Institutes of Health. In immunoblotting from cultured 
PTCs, commercially available antibodies (AQP1, Santa 
Cruz, cat. No. SC-20810; AQP7, Santa Cruz, cat. No. SC-
28625) were used.
7. Statistics
Values are presented as means ± SE. Comparisons be-
tween cyclophosphamide-treated and control rats were 
performed by the Mann-Whitney U-test. P values of less 
than 0.05 were considered statistically significant. 
Results 
1. Effects of cyclophosphamide administration on rat 
kidneys
Table 1 shows blood and urine data obtained on the 
final day of Animal Experiment I. Compared with vehicle-
treated controls, the 4 different doses (12, 24, 48, and 96 
mg/kg BW) of cyclophosphamide produced no significant 
changes in urine output, urine osmolality, plasma sodium 
and creatinine concentration, and creatinine clearance. 
The levels of AQP1 protein expression estimated in whole 
kidney homogenates were 100 ± 18%, 136 ± 53%, 244 
± 38%, 614 ± 194%, and 460 ± 46% at 0, 12, 24, 48, 
and 96 mg/kg BW doses, respectively. Thus, high doses of 
cyclophosphamide administration produced significant 
increases in AQP1 protein expression as compared with 
vehicle-treated controls (P < 0.005 at 48 mg/kg BW; P 
< 0.05 at 96 mg/kg BW). The expression of AQP2 pro-
tein also showed an increasing tendency at high doses 
of cyclophosphamide but did not reach the statistical 
significance (Fig. 1).
Table 2 shows blood and urine data obtained on the 
final day of Animal Experiment II. Although body weight 
Table 1. Blood and Urine Data from Animal Experiment I
0 mg/kg (n = 3) 12 mg/kg (n = 3) 24 mg/kg (n = 3) 48 mg/kg (n = 3) 96 mg/kg (n = 2)
Body weight (g) 259 ± 9 259 ± 4 251 ± 4 251 ± 5 247 ± 1
Urine volume (mL/100g BW) 15.8 ± 0.4 14.8 ± 0.2 18.8 ± 1.0 15.2 ± 2.1 10.5 ± 1.6
Urine sodium (µmol/day/100g BW) 1060 ± 12 993 ± 81 1025 ± 166 994 ± 80 756 ± 31
Urine osmolality (mOsm/kg H2O) 594 ± 25 544 ± 64 490 ± 43 628 ± 57 694 ± 112
Plasma sodium (mEq/L) 147.7 ± 0.3 147.3 ± 2.2 147.7 ± 0.7 148.3 ± 0.3 147.5 ± 0.5
Plasma creatinine (mg/dL) 0.57 ± 0.03 0.53 ± 0.03 0.53 ± 0.03 0.50 ± 0.00 0.50 ± 0.00
Creatinine clearance (µL/min/g BW) 2.11 ± 0.09 1.94 ± 0.16 2.01 ± 0.12 1.85 ± 0.11 1.68 ± 0.01
Data are mean  ± SE.  No significant differences in all parameters were found among the groups when comparisons were done by Kruskal-Wallis test.
BW, body weight.Electrolyte Blood Press 9:7-15, 2011 • doi: 10.5049/EBP.2011.9.1.7    11
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was steadily increased in both groups, weight gain was 
smaller in cyclophosphamide-treated rats than in controls 
(P < 0.05). Notably, cyclophosphamide-treated rats had 
lower plasma sodium concentration than controls (143 ± 
1 vs. 146 ± 1 mEq/L, P < 0.05). However, urine output, 
urine osmolality and sodium concentration, plasma 
creatinine concentration, and creatinine clearance were not 
significantly different between the 2 groups. 
Figure 2 shows the results of immunoblot analysis for 
AQP1 and AQP2 from renal cortices of Animal Experiment 
II. Cyclophosphamide treatment caused insignificant 
increases in both AQP1 (136 ± 20 vs. 100 ± 23%) and 
AQP2 (157 ± 18 vs. 100 ± 22%) protein expression. 
Figure 3 illustrates the results of reverse transcription PCR 
for AQP1, AQP2, vasopressin-2 receptor, and aquaporin-7 
(AQP7) from each RNA sample of renal cortex. QPCR, 
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Fig. 1. Immunoblot Analysis for Aquaporin-1 (AQP1) and Aquaporin-2 
(AQP2) from Whole Kidneys of Animal Experiment I. Each lane 
was loaded with a protein sample from a different rat. GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase.
*P < 0.05.
†P < 0.005 compared with vehicle-treated controls.
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Fig. 2. Immunoblot Analysis for Aquaporin-1 (AQP1) and Aquaporin-2 
(AQP2) from Rnal Cortices of Animal Experiment II. Each lane was 
loaded with a protein sample from a different rat. No statistically 
significant differences were found between the groups.
Table 2. Blood and Urine Data from Animal Experiment II
Parameters
Control 
(n = 6)
Treated 
(n = 6)
P*
Body weight (g) 306 ± 7 277 ± 4 < 0.05
Urine volume (mL/100g BW) 6.2 ± 1.0 4.3 ± 0.6 NS
Urine sodium (µmol/day/g BW) 8.0 ± 0.6 6.6 ± 0.6 NS
Urine osmolality (mOsm/kg H2O) 830 ± 125 971 ± 108 NS
Plasma sodium (mEq/L) 146.3 ± 1.3 142.8 ± 0.8 < 0.05
Plasma creatinine (mg/dL) 0.63 ± 0.02 0.62 ± 0.02 NS
Creatinine clearance (µL/min/g BW) 2.36 ± 0.19 2.26 ± 0.26 NS
Data are mean ± SE. BW, body weight; NS, not significant. 
*Comparisons by Mann-Whitney U test.  12      S Kim et al.• The Role of Proximal Nephron in Cyclophosphamide-Induced  Water Retention
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however, revealed no significant differences in mRNA levels 
between treated versus control rats (Fig. 4): AQP1, 75 ± 11 
vs. 100 ± 21%; AQP7, 105 ± 16 vs. 100 ± 13%; AQP2, 81 
± 14 vs. 100 ± 13%; and vasopressin-2 receptor, 96 ± 33 
vs. 100 ± 13%. 
2. Effects of 4-HC treatment on rabbit PTCs
In order to examine the effect of an active metabolite 
of cyclophosphamide on the expression of water channel 
proteins in primary cultured renal PTCs, we treated 
rabbit PTCs with 4-HC (0‒30 μmol/L) for 24 hours. In 
immunoblotting using membrane fraction of PTCs, protein 
expression levels of AQP1 and AQP7 were increased in a 
dose-dependent manner by 4-HC treatment (Fig. 5). 
Discussion
The kidney is able to regulate water excretion to maintain 
water balance. Renal conservation of water occurs partly 
in association with sodium reabsorption in the proximal 
tubule and thin limb of Henle’s loop and partly as a result 
of action of vasopressin on the collecting duct. AQP1 and 
AQP2 are the major water channels to mediate water 
reabsorption in the proximal nephron and collecting duct, 
respectively.    
Excessive accumulation of water results in dilutional 
hyponatremia. It usually occurs due to impaired renal ex-
cretion of water rather than excessive water intake because 
the capacity for water excretion normally is so great. 
When drugs affect water homeostasis, they can impair 
the renal diluting capacity in 3 ways
20). The first possibility 
Fig. 3. Reverse Transcription Polymerase Chain Reaction (PCR) 
from Renal Cortices of Animal Experiment II. Each lane was loaded 
with a cDNA sample from a different rat. AQP1, aquaporin-1; AQP2, 
aquaporin-2; V2R, vasopressin-2 receptor; AQP7, aquaporin-7; GAPDH, 
glyceraldehyde-3-phosphate dehydrogenase.
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Fig. 4. Quantitative Polymerase Chain Reaction (PCR) from Renal 
Cortices of Animal Experiment II. AQP1, aquaporin-1; AQP2, 
aquaporin-2; AQP7, aquaporin-7; V2R, vasopressin-2 receptor. No statis-
tically significant differences were found between the groups.Electrolyte Blood Press 9:7-15, 2011 • doi: 10.5049/EBP.2011.9.1.7    13
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is that they can increase vasopressin secretion centrally. 
However, plasma vasopressin levels are not elevated in 
patients following the administration of intravenous cy-
clophosphamide
21, 22). In addition, antidiuresis was reported 
to occur in response to intravenous cyclopho  sphamide in an 
8 year-old girl with central diabetes insipidus
23), excluding 
the possibility of a drug-induced syndrome of inappropriate 
antidiuretic hormone secretion (SIADH).
The second possibility is reset osmostat, lowering the 
threshold for vasopressin secretion. This condition is usually 
associated with a long-term course of hyponatremia such as 
spinal cord injury, psychiatric problems, and alcoholism
24), 
but cyclophosphamide-induced water retention is an acute 
process. The injection of cyclophosphamide into normally 
hydrated patients caused antidiuresis beginning in 4 to 12 
hours and lasting as long as 20 hours
25).
The third possibility is that cyclophosphamide may 
potentiate the action of vasopressin on the kidney. This 
postulation is very plausible, but has never been verified 
for decades. Recently, only carbamazepine was reported 
to increase AQP2 expression
26). In this study, the protein 
expression of AQP2 seemed to increase, although stati-
stical significance was not reached. Further studies 
will be required to demonstrate the role of AQP2 in 
cyclophosphamide-induced hyponatremia.
This study was focused to elucidate the role of the 
AQP1 water channel in cyclophosphamide-induced water 
retention. We tested whether AQP1 protein may be affected 
by cyclophosphamide administration in rat kidneys. In 
addition, primary cultured renal PTCs were treated with 
4-HC because the cyclophosphamide-induced antidiuresis 
was related to the urinary excretion of active alkylating 
metabolites of the drug
25).
To avoid the occurrence of hemorrhagic cystitis, we 
used moderate doses of a single cyclophosphamide 
administration. In Animal Experiment I, the increase in 
AQP1 protein expression was remarkable when 48 and 
96 mg/kg BW cyclophosphamide were administered 
(Fig. 1). However, hyponatremia was not found in these 
rats (Table 1). Considering that cyclophosphamide-
induced hyponatremia usually occurs 4‒12 hours after the 
intravenous administration of the drug, we may have to test 
an earlier change in plasma sodium level.
The results of Animal Experiment II suggest that the 
increase in AQP1 protein may persist for more than several 
days after a single cyclophosphamide administration (Fig. 
2). Cyclophosphamide-treated rats had a significantly lower 
plasma sodium concentration. Although weight gain was 
smaller in these animals, urine sodium excretion was not 
different between treated and control rats (Table 1). Thus 
we think that the main cause of hyponatremia in these 
cyclophosphamide-treated rats is water retention rather 
than hypovolemia.
Consistent with the animal studies, we found that 
treat  ment of primary cultured renal PTCs with an active 
metabolite of cyclophosphamide (4-HC) increased protein 
expressions of AQP1 and AQP7 in a dose-dependent 
manner (Fig. 5). Previous studies reported that AQP7 was 
localized selectively at the brush border membranes of 
proximal straight tubule (segment 3 proximal tubule, S3) 
in the rat kidney, suggesting that AQP7 may function as a 
pathway for transcellular water transport in S3 in concert 
with more widely expressed AQP1 in proximal tubules
27, 
28). Thus, the proximal nephron should be one of the 
major target sites where cyclophosphamide-induced water 
retention occurs. 
Despite the notable changes in AQP1 and AQP7 protein, 
we found no differences in the mRNA levels between 
cyclophosphamide-treated and control rats (Fig. 4). It 
is conceivable that other mechanisms such as decreased 
protein degradation than transcriptional regulation may 
exert to affect the AQP1 protein level. Further studies 
Fig. 5. Immunoblot for Aquaporin-1 (AQP1) and Aquaporin-7 
(AQP7) from Primary Cultured Rabbit Renal Proximal Tubule 
Cells. Cells were treated for 24 hours with each concentration of 
4-hydroperoxycyclophosphamide (4-HC).14      S Kim et al.• The Role of Proximal Nephron in Cyclophosphamide-Induced  Water Retention
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are required to demonstrate intracellular mechanisms to 
increase the protein abundance of AQP1 in response to 
cyclophosphamide administration. 
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